According to the US Food and Drug Administration (FDA), new guidance from the regulator could save biosimilar developers up to 50% of their pharmacokinetic (PK) study costs, or approximately $20m.
As part of an effort to lower drug costs, the FDA has made an announcement to facilitate the development of proposed